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metabolism (AβX-38, AβX-40, AβX-42 and Aβ1-42), solu-
ble amyloid precursor proteins (sAPP-α and sAPP-β), total 
tau (T-tau), phosphorylated tau (P-tau), and CSF/serum 
albumin ratio were measured in CSF using immunoassays. 
Heritability of the CSF markers was estimated, and asso-
ciations to psychiatric and cognitive measurements were 
analyzed. Heritability estimates of the microglia markers 
were moderate, whereas several neurodegenerative mark-
ers showed high heritability. In contrast, AβX-42, Aβ1-
42, P-tau and CSF/serum albumin ratio were influenced 
by dominant genetic variation. Higher sCD14 levels were 
found in twins with schizophrenia or bipolar disorder com-
pared to their not affected co-twins, and higher sCD14-
levels were associated with psychotic symptoms. The study 
provides support for a significant role of sCD14 in psy-
chotic disorders and a possible role of microglia activation 
in psychosis.
Keywords Schizophrenia · Bipolar disorder · Biomarker · 
Cerebrospinal fluid · Twin study · Neuroinflammation
Introduction
Bipolar disorder and schizophrenia are serious psychotic 
disorders associated with severe symptomatology and 
functional impairment. The lifetime prevalence for bipolar 
spectrum disorders is estimated at 2.4% [1] and at 0.4% for 
schizophrenia [2]. Epidemiological [3] and genetic stud-
ies [4] have found evidence of overlap, blurring the line 
between these disorders and suggesting common underly-
ing pathophysiological mechanisms.
Evidence from epidemiological studies [5–8] as well 
as postmortem and serological studies [9, 10] indicates an 
involvement of the immune system in schizophrenia and 
Abstract Schizophrenia and bipolar disorder are debilitat-
ing psychiatric disorders with partially shared symptoma-
tology including psychotic symptoms and cognitive impair-
ment. Aberrant levels of microglia and neurodegenerative 
cerebrospinal fluid (CSF) markers have previously been 
found in schizophrenia and bipolar disorder. We aimed to 
analyze familial and environmental influences on these 
CSF markers and their relation to psychiatric symptoms 
and cognitive ability. CSF was collected from 17 complete 
twin pairs, nine monozygotic and eight dizygotic, and from 
one twin sibling. Two pairs were concordant for schizo-
phrenia, and 11 pairs discordant for schizophrenia, schiz-
oaffective disorder or bipolar disorder, and four pairs were 
not affected by psychotic disorders. Markers of microglia 
activation [monocyte chemoattractant protein-1 (MCP-
1), chitinase 3-like protein 1 (YKL-40), and soluble clus-
ter of differentiation 14 (sCD14)], markers of β-amyloid 
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bipolar illness. Meta-analyses have shown that inflamma-
tory markers such as tumor necrosis factor α (TNF-α) and 
C-reactive protein (CRP) are elevated in both schizophrenia 
and bipolar disorder [11–14]. In the 1990s, it was proposed 
that chronically activated macrophages produce com-
pounds such as proinflammatory cytokines, which predis-
poses the brain for developing schizophrenia and mood dis-
orders [13, 15, 16]. This hypothesis has produced a number 
of studies on inflammatory mechanisms in psychiatric dis-
orders. Cluster of differentiation 14 protein (CD14) is a co-
receptor of the toll-like receptor (TLR) and is involved in 
microglia responses of the central nervous system (CNS) 
[17]. Recent studies found that the soluble form of CD14 
(sCD14) was higher in plasma from patients with schizo-
phrenia [18] and bipolar disorder compared with controls 
[19]. Another study using blood-derived monocytes from 
patients with bipolar disorder and controls found higher 
expression of inflammatory related genes in patients com-
pared with controls [20].
Although such studies—using peripheral blood as sub-
strate—provide evidence for systemic inflammation, they 
cannot readily be extrapolated to immunological activity 
in the brain. To study neuroinflammation and microglial 
activation, cerebrospinal fluid (CSF) is a more appropriate 
sampling substrate as it more closely reflects the brain bio-
chemistry [21]. Our research group recently found higher 
levels of monocyte chemoattractant protein-1 (MCP-1 also 
referred to as CCL-2), and chitinase 3-like protein 1 (YKL-
40) in CSF of bipolar patients compared with controls [19].
Cognitive impairment is a core symptom of schizophre-
nia [22] and is also present in bipolar spectrum disorders 
[23, 24]. In Alzheimer’s disease—where a progressive cog-
nitive decline occurs—the 42 amino acid form of amyloid 
β (Aβ-42) starts to accumulate in the brain 20–30 years 
before onset of symptoms [25], which is reflected by 
decreased CSF concentration of Aβ-42. Aβ buildup even-
tually triggers a neurotoxic cascade that involves hyper-
phosphorylation of the microtubule-stabilizing protein tau, 
which results in increased CSF concentrations of phospho-
rylated tau (P-tau), and neuroaxonal degeneration, which 
is reflected by increased CSF concentrations of total tau 
(T-tau) [26]. Lower CSF concentrations of amyloidogenic 
Aβ1-42 have been found in elderly patients with schizo-
phrenia compared to controls [27]. In a postmortem study, 
schizophrenia patients with cognitive decline showed 
higher levels of senile plaques than those without cognitive 
decline [28], but a recent review concluded that Aβ deposi-
tion was not associated with cognitive decline in late-life 
schizophrenia in most studies [29]. In bipolar disorder, 
lower CSF levels of soluble amyloid precursor protein α 
(sAPP-α) and β (sAPP-β) were detected compared with 
controls, along with higher ratios of AβX-42 in relation to 
amyloid β-38 (AβX-38) and Aβ-amyloidβ-40 (AβX-40) 
in bipolar patients [30]. Lower plasma levels of Aβ-42 
and higher Aβ40/Aβ42 ratios were found in a sample of 
patients with bipolar disorder or depression. The findings 
indicate a possible disturbance of the amyloid turnover also 
in bipolar disorder [31].
An important limitation with these prior studies on CSF 
microglia and neurodegenerative markers in bipolar disor-
der is the cross-sectional case–control design where it is 
not possible to separate genetic contributions (trait) from 
the effect of the disease (state). One possible solution is to 
study twins, which may allow disentangling genetic, shared 
environmental, and unique environmental influences on 
CSF markers. We have previously used a twin model to 
examine the association between microscopic structures in 
CSF and psychosis in twins with schizophrenia and bipolar 
disorder [32, 33].
In the present study, we investigated CSF markers in 
17 complete twin pairs with schizophrenia or bipolar dis-
order and in one twin sibling. We analyzed three immune-
related markers (sCD14, YKL-40, and MCP-1), six amy-
loid-related markers (AβX-38, AβX-40, AβX-42, Aβ1-42, 
sAPP-α, sAPP-β), along with T-tau and P-tau. The aim was 
to estimate the heritability of the CSF markers and to ana-
lyze the genetic and environmental influences of the ana-
lyzed markers in a co-twin control design, as well as to 
study associations between psychotic symptoms in relation 
to the CSF markers. We also examined the CSF markers in 
relationship to other personality and cognitive variables in 
a set of exploratory analyses.
Methods
Recruitment of twin subjects
The twin pairs were recruited from a nationwide study of 
Swedish-born, same-sex twins with schizophrenia, schiz-
oaffective disorder, bipolar disorder, and healthy control 
pairs [32]. All study subjects were originally recruited 
through the Swedish Twin Registry. In total, 18 complete 
twin pairs were included but one sibling from one of the 
recruited pairs did not agree to undergo lumbar puncture 
which left us with 35 twin individuals. All 35 twins con-
sented orally and in writing to participate and received a 
small remuneration for their participation. The study was 
approved by the Ethical Review Board, Stockholm, and was 
performed in compliance with the Helsinki Declaration.
Assessment procedures
All study participants first completed screening forms of 
The Structured Clinical Interview for DSM-IV Axis I Dis-
orders (SCID-I) [34] and Axis II Disorders (SCID-II) [35] 
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and the self-assessment questionnaires Schizotypal Per-
sonality Questionnaire Brief (SPQ-B), [36], Barratt Impul-
siveness Scale (BIS-11) [37], Zuckerman sensation seek-
ing scale (ZSSS) [38] and the Temperament Evaluation 
of Memphis, Pisa, Paris and San Diego-autoquestionnaire 
(TEMPS-A) [39]. BIS-11 measures the following dimen-
sions: attentional, motor, and nonplanning factors. TEMPS-
A measures the following affective temperaments: cyclo-
thymic, dysthymic, irritable, hyperthymic, and anxious. 
The subjects were then interviewed with SCID-I and SCDI-
II. Psychotic symptoms were assessed by a rater through 
the Scale for Assessment of Negative Symptoms (SANS) 
[40] and the Scale for Assessment of Positive Symptoms 
(SAPS) [41]. The level of functioning was rated using the 
Global Assessment Function scale (GAF, American Psy-
chiatric Association 1994). Subsequently the subjects were 
administrated the vocabulary and the block design subtests 
of the Wechsler Abbreviated Scale of Intelligence (WASI) 
and the California Verbal Learning test (CVLT). Informa-
tion on socioeconomic status, smoking habits, and somatic 
status was collected. As the lumbar puncture was per-
formed after the initial psychiatric assessment, a comple-
mentary psychiatric assessment was performed the same 
day as the lumbar puncture to update information on psy-
chiatric status, current medication, and somatic status. All 
patients were in remission at the time of the lumbar punc-
ture. Finally, the diagnoses were reviewed by two of the 
investigators (CMH and VJ) considering information from 
diagnostic assessments, medical records, and a full his-
tory of lifetime psychiatric diagnostic codes of the Swed-
ish National Patient Register (National Board of Health and 
Welfare, http://www.socialstyrelsen.se) covering the period 
1973–2009.
Zygosity determination
The zygosity of the twins, MZ or DZ, was validated using 
a panel of 47 highly multiplexed single-nucleotide poly-
morphisms (SNP) [42] that provide reliable and high-qual-
ity data on a range of different DNA templates. Of the 35 
twins recruited for this study, 19 individuals were MZ and 
16 DZ.
Diagnosis and antipsychotic medication
There were in total 15 probands with either schizophrenia 
(n = 6), schizoaffective disorder (n = 2), bipolar disor-
der type I (n = 4), or bipolar disorder type II (n = 3), 12 
unaffected co-twins, and eight healthy twin controls. In 
the overall statistical analyses, we collapsed the diagno-
ses schizophrenia, schizoaffective disorder, bipolar disor-
der I and II into one category designated ‘psychotic dis-
order.’ In secondary analyses, we collapsed the diagnoses 
schizophrenia and schizoaffective disorder into one cate-
gory designated ‘schizophrenia’ and bipolar disorder type 1 
and 2 into one category designated ‘bipolar disorder.’ Nine 
out of 15 probands were prescribed antipsychotic medica-
tion of the following types: haloperidol, levomepromazine, 
olanzapine, perphenazine, quetiapine and risperidone.
Collection of cerebrospinal fluid
The sampling of CSF took place during March 2008–Sep-
tember 2011. The same clinical neurologist performed the 
35 lumbar punctures. With study participant in the sitting 
position, the needle was inserted in vertebral interspace L3/
L4, or L4/L5. The very first drops of CSF, approximately 
0.6 mL, were used for microscopic examination while the 
following 12 mL of CSF was collected, gently inverted to 
avoid gradient effects, and divided into 1.0–1.6 mL aliquots 
that were stored at minus 80 °C pending analysis.
Blood sampling and BMI
Blood samples were collected before the lumbar puncture 
with the subjects fasting at 0800 h. High-sensitivity C-reac-
tive protein (HS-CRP) and the white blood cell count 
(WBC) were measured. Height and weight were recorded 
on the same day as blood and CSF sampling and used for 
calculation of the body mass index (BMI) as a heuristic 
proxy for body fat of the participants.
Analysis of blood–CSF barrier function
Albumin levels in CSF and serum were measured at the 
Clinical Neurochemistry Laboratory in Mölndal, Sweden, 
by immunonephelometry on a Beckman Immage Immuno-
chemistry system (Beckman Instruments, BeckmanCoul-
ter, Brea, CA, USA). The method was accredited by the 
Swedish Board for Accreditation and Conformity Assess-
ment (SWEDAC). Experienced and board-certified labora-
tory technicians who were blinded to clinical information 
performed all measurements. Intra- and inter-assay coef-
ficients of variation were below 10%. To assess the blood 
CSF barrier function, the ratio between albumin concentra-
tion in CSF (mg/L) and serum (g/L) was calculated.
CSF marker analyses
The CSF concentrations of MCP-1, sAPP-α and sAPP-β, 
and AβX-38, AβX-40, and AβX-42 were determined 
using the MSD® Human MCP-1 Ultra-Sensitive Kit, 
MSD® sAPP-α/sAPP-β Multiplex Assay, and MSD ® 
Human/Rodent (4G8) Abeta-Triplex Assay, respectively, 
as described by the manufacturer (Meso Scale Discovery, 
Gaithersburg, MD, USA). CSF concentrations of P-tau, 
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T-tau, and Aβ1-42 were measured simultaneously by the 
Luminex xMAP technology using the Inno-Bia AlzBio3 kit 
(Innogenetics, Zwijndrecht, Belgium). The MSD-derived 
Aβ concentrations were derived using a detection anti-
body against the mid-domain of the Aβ proteins, whereas 
we also measured Aβ-42 using the AlzBio3 kit. This kit 
includes a neo-epitope-specific antibody against the first 
amino acids of Aβ. For this reason, we denote MSD-
derived Aβ concentrations AβX-38, AβX-40 and AβX-42 
and AlzBio3-derived Aβ concentrations Aβ1-42 through-
out the manuscript. sCD14 and YKL-40 were determined 
by Human sCD14 quantikine ELISA kit and Human chi-
tinase-3 quantikine ELISA kit, respectively (R&D systems, 
Inc, Minneapolis, MN). All CSF analyses were performed 
in one round of analyses using one batch of reagents by 
board-certified laboratory technicians who were blinded to 
clinical information.
Statistical analyses
Demographics, disease characteristics, and pharmacologi-
cal treatment are presented as percentages, means (standard 
deviations), or medians (max, min-scores). For correlations, 
Pearson’s correlation coefficients were calculated where 
the markers were normally distributed else Spearman’s 
correlation was calculated and Fishers Z-transformation 
was used to compute confidence intervals. For heritability 
estimation, we performed structural equation modeling of 
the observed covariance in MZ and DZ twin pairs to find 
maximum likelihood estimates for additive genetic effects 
(A), shared environmental effects (C), unique environmen-
tal effects (E), and dominant genetic effects (D). Standard-
ized maximum likelihood estimates were squared to yield 
proportions of phenotypic variance accounted for by each 
term. We tested model fit of ACE, ADE, AE, DE, CE, and 
E models using the χ2 statistic, the root-mean-square error 
of approximation (RMSEA), and the Akaike information 
criterion (AIC). The AIC is a relative measure of fit [43]. 
Lower values indicate a better fit, and the score penalizes 
additional parameters and therefore favors parsimonious 
models [44].
In the co-twin control analysis of the disease-discordant 
twin pairs, the Shapiro–Wilk test of normality of the intra-
pair differences showed that all markers were normally dis-
tributed. We therefore used the paired t test in all co-twin 
control analyses. Associations between CSF markers and 
psychometric scales and neurocognitive testing results and 
clinical characteristics were analyzed with a mixed linear 
regression model with random intercepts shared within 
the twin pairs with age and sex included as covariates. The 
CSF markers entered the model as the dependent variable 
(outcome) and the scales results or confounding factors 
as independent variables (exposure). The same model was 
used to test differences between probands (patients with 
schizophrenia, bipolar disorder, or schizoaffective disor-
der), unaffected co-twins and healthy controls. Also here 
the CSF markers entered the model as dependent (out-
come) variable.
Log transformations were applied when the data were 
not normally distributed which included the following CSF 
markers: sCD14, sAPP-α, sAPP-β, tau, p-tau, and the CSF/
serum albumin ratio. Given the unique nature of the study, 
no adjustments were made for multiple testing, as we pre-
ferred to generate potential findings of interest that could 
be verified in future studies instead of missing potential 
findings of interest as might be the case with a Bonferroni 
correction. All analyses were performed using the SAS 9.4 
statistical software (SAS Institute Inc, USA) except for 
the structural equation modeling where we employed the 
matrix algebra program Mx [45].
Results
We obtained CSF from in total 35 twins belonging to 17 
complete twin pairs and one single twin. Eleven of the pairs 
were discordant for schizophrenia, schizoaffective disorder, 
or bipolar disorder. Two pairs were concordant for schizo-
phrenia, and four twin pairs were control pairs. Character-
istics of the twins are presented in Table 1.
Heritabilities of the CSF markers
Table 2 presents the heritability analyses of the microglia 
markers and the neurodegenerative proteins measured in 
CSF. The additive genetic effects on the microglia mark-
ers sCD14 and YKL-40 were moderate, while MCP-1 was 
entirely driven by environmental effects. High heritability 
estimates were found for sAPP-α, sAPP-β, and AβX-38, 
while the heritability of AβX-40 was moderate. AβX-42 
and Aβ1-42 were influenced by non-additive (dominant) 
genetic effects. The heritability of T-tau and its phospho-
rylated isoform P-tau were high, with additive variation 
contributing to T-tau and dominant variation to P-tau in the 
best fitting models. CSF/serum albumin ratio, a proxy for 
the function of the CSF-blood barrier, was influenced by 
dominant genetic variation.
Co‑twin control analysis of CSF markers in the 
disease‑discordant twin pairs
We continued with a co-twin control analysis of the CSF 
markers in twin pairs discordant for any psychotic disorder 
(schizophrenia, schizoaffective disorder or bipolar disorder, 
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n = 11). We found significantly higher levels of sCD14 in 
the probands affected with a psychotic disorder compared 
to their non-affected co-twins, (Table 3; Fig. 1). None of 
the other markers showed any statistically significant dif-
ference within the pairs. We then performed a co-twin 
control analysis of sCD14 stratified by zygosity, psychotic 
diagnosis (schizophrenia/schizoaffective disorder or bipo-
lar disorder), and by antipsychotic medication. The abso-
lute sCD14 levels were higher in the probands compared to 
the co-twins in the MZ twin pairs, but the differences did 
not reach the significant level (Table 4). In the twin pairs 
with schizophrenia or schizoaffective disorder, sCD14 was 
significantly higher in probands compared to controls. No 
significant differences of sCD14-levels were seen within 
the pairs where the probands were medicated with antip-
sychotics and within the pairs where the probands did not 
have antipsychotics (Table 4).  
Associations between psychotic symptoms 
and personality traits and CSF markers
We analyzed associations between the CSF markers and 
psychometric scales for psychosis that included SAPS, 
SANS, SPQ-B, and the SCID-II screen (cluster A section). 
Table 5 shows that significant associations were found 
between higher sCD14 levels and higher scores from the 
SANS scale and the SCID-II screening (cluster A section). 
Further analysis showed associations between sCD14 and 
Table 1  Characteristics of the twin cohort divided into probands, co-twins, and controls (left hand side), and monozygotic and dizygotic twins 
(right hand side)
MZ monozygotic, CRP C-reactive protein, SD standard deviation
a Living with partner
b Defined as studies on University level
Proband n = 15 Co-twin n = 12 Control n = 8 Monozygotic n = 19 Dizygotic n = 16
N (%) or mean ± SD N (%) or mean ± SD N (%) or mean ± SD N (%) or mean ± SD N (%) or mean ± SD
Sex, male 5 (33.3) 4 (33.3) 8 (100) 9 (47.4) 8 (50.0)
Age 52.4 ± 9.6 51.1 ± 10.6 56.5 ± 5.9 54.2 ± 10.8 51.4 ± 6.9
Zygosity, MZ 8 (53.3) 7 (58.3) 4 (50.0)
Cohabitationa 2 (15.4) 5 (41.7) 3 (37.5) 5 (29.4) 5 (31.25)
Educationb 6 (40.0) 6 (50.0) 2 (25.0) 7 (36.8) 7 (43.8)
Smoke 7 (46.7) 1 (8.3) 3 (37.5) 5 (26.3) 6 (37.5)
Snuff 5 (33.3) 1 (8.3) 0 (0) 4 (21.1) 2 (12.5)
Body mass index 28.8 ± 7.9 27.5 ± 6.0 24.5 ± 2.1 27.2 ± 5.8 27.6 ± 7.2
Psychiatric diagnoses
Schizophrenia 6 (40.0) – – 3 (15.8) 3 (18.8)
Schizoaffective disorder 2 (13.3) – – 1 (5.3) 1 (6.3)
Bipolar disorder type I 4 (26.7) – – 3 (15.8) 1 (18.8)
Bipolar disorder type 2 3 (0.2) – – 1 (5.3) 2 (12.5)
Age of onset 26.8 ± 9.8 (n = 14) 24.1 ± 10.7 (n = 8) 30.3 ± 8 (n = 6)
GAF [median (min–max)] 55 (35–80) 75 (50–100) 75 (70–90) 70 (35–90) 70 (40–100)
Laboratory data
Albumin ratio 5.8 ± 1.6 4.7 ± 1.8 7.7 ± 4.0 6.5 ± 2.9 5.1 ± 2.0
Blood leukocytes 6.6 ± 2.1 5.9 ± 1.3 6.9 ± 2.8 6.5 ± 2.2 6.4 ± 1.8
High-sensitivity CRP 1.3 ± 1.3 (n = 13) 3.9 ± 5.8 (n = 11) 7.7 ± 8.3 (n = 7) 4.1 ± 6.1 (n = 17) 3.3 ± 5.3 (n = 14)
CRP 6.3 ± 5.3 (n = 2) 6.0 ± 0 (n = 1) 5.2 ± 0 (n = 1) 8.0 ± 2.8 (n = 2) 3.9 ± 1.9 (n = 2)
Medication
Lithium 4 (26.7) 0 (0) 0 (0) 2 (10.5) 2 (12.5)
Anticonvulsant 3 (20.0) 0 (0) 0 (0) 1 (5.3) 2 (12.5)
Antipsychotic 9 (60.0) 0 (0) 0 (0) 5 (26.3) 4 (25.0)
Antidepressant 5 (33.3) 3 (25.0) 2 (25.0) 5 (26.3) 5 (31.3)
Somatic medication 7 (46.7) 3 (25.0) 4 (50.0) 7 (36.8) 7 (43.8)
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the paranoid (t = 2.73, p = 0.016) and schizotypal person-
ality traits of the SCID-II screening (t = 3.39, p = 0.0041).
Associations between other psychometric scales, 
cognitive functions, and CSF markers
We did an overall screening of associations between the CSF 
markers and the following psychometric assessment scales: 
SCID-II screening (cluster B and C section), BIS-11, ZSSS 
and TEMPS-A, and the neuropsychological tests of WASI 
vocabulary, WASI block design, and CVLT. An association 
was identified between sCD14 and scores from the BIS-11 
scale measuring impulsiveness, in particular with the atten-
tional dimension of impulsiveness (Supplement Table).
Relationship between clinical characteristics and CSF 
markers
Associations between the CSF markers and the following 
factors were analyzed: CSF/serum albumin ratio, smok-
ing, snuff use, ongoing or previous alcohol dependence, 
BMI, measures of peripheral inflammation in serum (HS-
CRP and WBC), and psychotropic medication (antipsy-
chotics, lithium, antidepressants, and anticonvulsants). 
Associations were found between CSF/serum albumin 
ratio and sCD14 (t = 5.04, p < 0.0001) and CSF/serum 
albumin ratio and YKL-40 (t = 2.31, p = 0.03). Asso-
ciations were also found between lithium use and AβX-
38 (t = −2.54, p = 0.021) and AβX-40 (t = −2.52, 




Dizygotic twin correlations χ2 p value Best-fitted model Model terms ACED-
model
r (CI) r (CI) A C E D
sCD14 0.96 (0.83–0.99) 0.73 (0.05–0.95) 73.8 <.001 ACE 0.33 0.33 0.33
YKL-40 0.80 (0.30–0.96) 0.66 (−0.08–0.93) 84.6 <.001 ACE 0.35 0.31 0.35
MCP-1 0.44 (−0.31–0.85) 0.16 (−0.61–0.78) 4.05 0.54 E
sAPP-α 0.85 (0.43–0.97) 0.40 (−0.42–0.86) 2.07 0.56 ACE 0.86 0.00 0.14
sAPP-β 0.75 (0.16–0.94) 0.33 (−0.48–0.84) 2.89 0.41 ACE 0.79 0.00 0.21
AβX-38 0.88 (0.50–0.97) 0.00 (−0.70–0.70) 3.76 0.29 ACE 0.68 0.19 0.14
AβX-40 0.87 (0.50–0.97) 0.06 (−0.68–0.73) 7.04 0.07 ACE 0.33 0.12 0.55
AβX-42 0.62 (−0.08–0.91) 0.01 (−0.70–0.71) 3.63 0.46 DE 0.46 0.54
Aβ1-42 0.57 (−0.15–0.90) 0.19 (−0.59–0.79) 2.98 0.56 DE 0.46 0.54
T-Tau 0.91 (0.61–0.98) 0.42 (−0.41–0.87) 5.51 0.24 AE 0.77 0.23
P-tau 0.85 (0.43–0.97) 0.36 (−0.46–0.85) 7.94 0.09 DE 0.22 0.78
CSF/serum albumin ratio 0.46 (−0.29–0.86) −0.02 (−0.72–0.69) 3.05 0.55 DE 0.26 0.74
Table 3  Results of the 
co-twin control analysis of the 
cerebrospinal fluid markers 
in the disease-discordant twin 
pairs
Significant results are bolded
SD standard deviation
Proband (n = 11) Co-twin (n = 11) Intrapair difference Paired t test
Mean SD Mean SD Mean SD p value
sCD14 (pg/ml) 102,930 26,431 86,843 28,607 16,086 17,847 0.0136
YKL-40 (pg/ml) 112,630 33,181 103,646 37,230 8984 26,791 0.2921
MCP-1 (pg/ml) 629 90.1 599 128 29.7 158 0.5468
AβX-38 (pg/ml) 1720 511 1633 473 87.2 497 0.5733
AβX-40 (pg/ml) 9889 2665 9422 2346 468 2574 0.5605
AβX-42 (pg/ml) 1117 280 988 251 129 337 0.2321
Aβ1-42 (pg/ml) 809 126 712 150 96.7 173 0.0929
sAPP-α (ng/ml) 833 380 806 270 26.8 263 0.7419
sAPP-β (ng/ml) 466 192 436 140 30.5 155 0.5286
T-tau (pg/ml) 294 89.4 299 166 −4.7 140 0.9128
P-tau (pg/ml) 38.7 10.2 38.6 18.6 0.1 14.6 0.9792
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p = 0.023); antidepressant medication and MCP-1 
(t = 2.73, p = 0.015); smoking and sAPP-α (t = −3.13, 
p = 0.007) and sAPP-β (t = −3.75, p = 0.002); and 
between snuff use and sAPP-α (t = −3.37, p = 0.004), 
sAPP-β (t = −2.82, p = 0.012), AβX-38 (t = −2.64, 
p = 0.018) and AβX-40 (t = −2.65, p = 0.018).
Exploring the association between CSF/serum albumin 
ratio and sCD14 and YKL‑40
In this study and in a previous report, associations were 
identified between CSF/serum albumin ratio and the 
microglia markers sCD14 and YKL-40 [46]. The complete 
twin pairs (n = 17) were used to explore the mechanisms 
of these associations. In 14 out of the 17 MZ and DZ pairs, 
the twin in a pair with the higher sCD14 level also had the 
higher CSF/serum albumin ratio. Correlations of the twin 
pair difference scores were calculated (twin 1 minus twin 
2) of CSF/serum albumin ratio and sCD14, and we found a 
higher correlation in the DZ pairs [r(8) = 0.81, p < 0.015] 
compared to the MZ pairs [r(9) = 0.10, p = 0.80], Fig. 2. 
The correlations of the difference sores between YKL-
40 and CSF/serum albumin ratio were not significant in 
the DZ pairs [r(8) = 0.52, p = 0.18] nor in the MZ pairs 
[r(9) = −0.53, p = 0.14]. These results are not in accord-
ance with a causal hypothesis where higher CSF/serum 
albumin ratio causes higher levels of sCD14 or YKL-40.
Associations of CSF marker levels in probands, 
unaffected co‑twins, and controls
The traditional proband-co-twin control analysis was not 
the most suitable statistical model due to a limited num-
ber of control pairs in our sample. As expected, given the 
results from the co-twin control analysis, significantly 
higher levels of sCD14 were found in the probands com-
pared to the co-twins (t = 3.28, p = 0.0066).
Discussion
Previous studies have reported aberrant levels of micro-
glia and neurodegenerative markers in serum and CSF in 
patients with psychotic disorders [18, 30, 46]. Here, we 
Fig. 1  Comparison of sCD14 levels between the twin pairs where the 
probands are affected with schizophrenia or bipolar disorder and the 
co-twins are not affected and the line represents each pair (n = 11)
Table 4  Co-twin control 
analysis of sCD14 in 
cerebrospinal fluid stratified 
by zygosity, diagnosis in the 
proband, and antipsychotic 
medication in the proband
Significant results marked as bolded
SD standard deviation, MZ monozygotic twin pair, DZ dizygotic twin pair, SCZ schizophrenia, SA schiz-
oaffective disorder, BPD bipolar disorder
a  MZ/DZ pairs n = 2/n = 2
b  MZ/DZ pairs n = 4/n = 3
c  MZ/DZ pairs n = 3/n = 3
d  MZ/DZ pairs n = 3/n = 2
Proband (n = 11) Co-twin (n = 11) Intrapair difference Paired t test
Mean SD Mean SD Mean SD p value
Zygosity
MZ n = 6 102,761 30,605 97,184 30,286 5578 6322 0.0831
DZ n = 5 103,133 23,994 74,436 23,378 28,697 19,544 0.0304
Diagnosis
SCZ/SA, n = 4a 96,697 31,698 75,097 34,061 21,600 13,318 0.0477
BPD, n = 7b 106,492 24,926 93,556 25,284 12,936 20,258 0.1421
Antipsychotics
Yes, n = 6c 98,023 26,623 85,112 32,426 12,911 16,972 0.1214
No, n = 5d 108,819 27,949 88,922 26,865 19,897 20,075 0.0910
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Table 5  Results from the mixed regression analysis between the CSF markers and psychometric scales for psychotic symptoms and personality 
traits
SE standard error, SANS scale for assessment of negative symptoms, SAPS scale for assessment of positive symptoms, SPQ-B schizotypal per-
sonality questionnaire brief, SCID-II the structured clinical interview for DSM-IV Axis II disorders
SANS SAPS
Estimate SE t value p value Estimate SE t value p value
MCP-1 0.10 0.86 0.12 0.91 1.05 1.80 0.58 0.57
YKL-40 256 263 0.97 0.35 401 432 0.93 0.37
sCD14 0.0021 0.0009 2.28 0.037 0.0029 0.0015 1.99 0.064
sAPP-α −0.0009 0.0013 −0.67 0.51 −0.0031 0.0021 −1.45 0.17
sAPP-β −0.0001 0.0013 −0.10 0.92 −0.0011 0.0021 −0.52 0.61
AβX-38 0.98 4.15 0.24 0.81 −0.65 7.18 −0.09 0.93
AβX-40 5.74 21.6 0.27 0.79 −18.58 36.91 −0.50 0.62
AβX-42 2.86 2.59 1.10 0.29 2.21 4.72 0.47 0.65
Aβ1-42 2.38 1.41 1.68 0.11 2.62 2.62 1.00 0.33
T-tau 0.0007 0.0012 0.61 0.55 0.0001 0.0020 0.07 0.95
P-tau 0.001 0.0011 1.04 0.31 0.0009 0.0018 0.49 0.63
SPQ-B SCID-II—cluster A
MCP-1 4.11 3.66 1.12 0.28 1.72 3.46 0.50 0.63
YKL-40 57.6 1045 0.06 0.96 1774 884 2.01 0.063
sCD14 0.0062 0.0036 1.72 0.10 0.011 0.003 3.70 0.0021
sAPP-α −0.0052 0.0051 −1.02 0.32 −0.0099 0.0047 −2.09 0.054
sAPP-β −0.0014 0.0050 −0.29 0.78 −0.0063 0.0047 −1.34 0.20
AβX-38 −2.6 16.57 −0.16 0.88 −4.71 16.04 −0.29 0.77
AβX-40 −31.49 86.15 −0.37 0.72 −39.88 83.45 −0.48 0.64
AβX-42 5.78 10.67 0.54 0.60 4.55 10.28 0.44 0.66
Aβ1-42 4.93 5.936 0.83 0.41 4.56 5.69 0.80 0.43
T-tau −0.0014 0.0047 −0.29 0.77 0.0021 0.0047 0.45 0.66
P-tau 0.0001 0.0042 0.03 0.97 0.0037 0.0041 0.90 0.38
Fig. 2  Correlations of the difference scores between the twin pairs (n = 17) of CSF/serum albumin ratio in relation to the CSF markers sCD14 
and YKL-40
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estimated the heritability of 11 CSF markers in 17 twin 
pairs and performed a co-twin control analysis of the CSF 
markers in 11 pairs discordant for schizophrenia, schiz-
oaffective disorder or bipolar disorder. In addition, we 
analyzed the relationship between the CSF markers and 
psychotic symptoms and cluster A personality traits, and 
finally, with an exploratory agenda, we analyzed the CSF 
markers in relation to additional personality traits and cog-
nitive ability.
Our main findings include the moderate to high her-
itabilities of many included markers. We identified that 
AβX-42, Aβ1-42, P-tau, and CSF/serum albumin ratio 
were affected by dominant genetic variation, while MCP-1 
was driven by environmental influences only in best fitting 
models. We also found two pieces of evidence of a possi-
ble role of sCD14 in psychotic disorder. First, higher CSF 
levels of sCD14 were found in the twins with psychosis 
compared to their unaffected co-twins. Second, associa-
tions were found between sCD14 and negative psychotic 
symptoms and paranoid and schizotypal personality traits. 
Finally, we observed a novel association between sCD14 
and impulsiveness related to attention, and associations 
between sCD14 and borderline, antisocial, and narcis-
sistic personality traits. The findings indicate that sCD14 
partially might be involved in or reflect the disease pro-
cesses of schizophrenia and bipolar disorder and that it may 
increase with disease severity.
No previous heritability study has been performed on 
the present CSF markers. In a prior report, the heritability 
of MCP-1 concentrations in serum was 0.63, indicating that 
more than 50% of the variance was due to additive genetic 
factors [47]. In CSF, however, we found that MCP-1 was 
primarily driven by unique environmental factors. This may 
reflect different mechanisms behind the MCP-1 expression 
in CNS compared to the periphery or a sample size issue. 
The amyloid markers, and in particular the sAPP-pro-
teins, were influenced by additive genetics. In sAPP-α, we 
observed an additive genetic effect of 86%, while AβX-42 
and Aβ1-42 appeared equivalently heritable due primarily 
to dominant genetic influences. Another interesting find-
ing was a high additive genetic effect on T-tau, whereas its 
phosphorylated form, P-tau, was influenced by dominant 
genetic effects. The Aβ1-42 peptide and P-tau are both 
markers for Alzheimer’s disease. The results may indicate 
that interactive genetic effects could affect the regulation of 
the markers of Alzheimer’s disease rather than many genes 
with small and additive effects. However, it must be kept 
in mind that the sample sizes were low, and it is possible 
that the genetic effects attributed to dominance are actually 
additive genetic influences.
We found associations between higher sCD14 levels 
in CSF and negative psychotic symptoms, paranoid and 
schizotypal personality traits, and a trend association to 
positive psychotic symptoms. Further, we found higher lev-
els of sCD14 in twins with schizophrenia, schizoaffective 
or bipolar disorder compared to their not affected co-twins. 
Previous studies have reported that a C to T base exchange 
at position 159 in the promoter region of the CD14 gene 
resulted in an elevated gene expression, leading to higher 
CD14 levels [48, 49]. Another study that investigated the 
genotype distribution of the CD14 C159T SNP did not find 
any difference between patients with schizophrenia and 
controls [50]. Those results are not incompatible with our 
finding of higher sCD14 levels in the twins with psychosis 
as the result in this report suggests a partial influence of the 
unique environment on the sCD14 levels, although we were 
not able to analyze the MZ pairs separately due to lack of 
power.
In the CNS, sCD14 is produced by activated mac-
rophages triggered by the immune system [51, 52] and 
sCD14 has been suggested to be involved in microglial 
activation [17, 53, 54]. In addition, it has been shown pre-
viously that serum and CSF levels of sCD14 are uncor-
related, indicating that the finding of higher CSF sCD14 
levels is CNS specific [19]. Antipsychotic medication may 
also give rise to higher sCD14 levels, but in the co-twin 
control analysis we could not find any difference between 
the twin pairs discordant for antipsychotic medication and 
without antipsychotics and no association between sCD14 
and antipsychotic medication was found in the regression 
analysis. The association between higher sCD14 levels and 
psychosis thus provide further evidence for a role of micro-
glia activation in psychotic disorders.
An interesting finding was the strong association 
between sCD14 and CSF/serum albumin ratio. Increased 
CSF/serum albumin ratio may indicate a disturbed func-
tion of the blood–CSF barrier, and a recent study suggests 
that this may contribute to increased brain levels of proin-
flammatory cytokines [55]. Previous studies have demon-
strated higher CSF/serum albumin ratio levels in patients 
with schizophrenia and bipolar disorder [56, 57] as well 
as a correlation to negative psychotic symptoms [58]. We 
hypothesized that the higher sCD14 levels in CSF would 
be a consequence of an increased influx of proteins from 
serum to the CSF due to worsened integrity of the blood–
CSF-barrier. Thus, we explored the association between 
sCD14 and CSF/serum albumin ratio by analyzing the cor-
relation of the difference scores within the twin pairs. The 
result, however, was not consistent with a causal relation-
ship between CSF/serum albumin ratio and sCD14, and 
despite an association the markers may be independent.
A previous study demonstrated lower CSF Aβ-42 levels 
in carriers of the ε4 allele of the apolipoprotein E (APOE) 
gene [59], but recent data show that this is mediated via the 
association of ε4 with senile plaque pathology in Alzheimer’s 
disease [60]. Moreover, associations have been observed 
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between the APOE gene and vascular regulation in schizo-
phrenia [61], but a recent meta-analysis did not find the 
APOE gene to be a risk factor in schizophrenia [62]. In the 
present study, we found no associations between the neurode-
generative markers (amyloid- and tau-proteins) and psychiat-
ric symptoms or cognitive ability which is consistent with the 
view that psychosis is not a classical neurodegenerative dis-
order with major cell atrophy as in, e.g., Alzheimer’s disease.
Finally, we screened the results from the psychometric 
scales and cognitive ability against the 11 CSF markers. 
We found an association between sCD14 and impulsivity, 
in line with some previous work suggesting a relationship 
between immune functioning and impulsivity [63, 64]. In 
addition, in a study from our research group it was found 
that increased impulsivity may be a part of the endophe-
notype of patients with schizophrenia and bipolar disor-
der [65]. Future work examining the relationship between 
impulsivity and sCD14 may be of interest.
Strengths of this study include the unique collection of 
CSF from twins concordant and discordant for schizophre-
nia or bipolar disorder. The participants were thoroughly 
phenotyped and reexamined in conjunction to lumbar punc-
ture. However, it is challenging to recruit twin pairs con-
cordant and discordant for psychotic disorder volunteering 
for a spinal tap. The sample size of this study is therefore 
limited. We performed several tests and the obtained results 
would not withstand correction for multiple testing. In bal-
ancing the risk for type I and type II errors, we opted for 
presenting the results without correction for multiple test-
ing. This means that there is a risk for false-positive find-
ings, and results should be regarded as preliminary pending 
future replications in larger twin samples.
In summary, in a unique sample of twins with and with-
out psychotic disorders, we demonstrated for the first time 
higher CSF sCD14 levels in twins with a diagnosis of 
schizophrenia or bipolar disorder compared to unaffected 
co-twins. This difference is interpreted as partly attribut-
able to environmental factors such as inflammation within 
the CNS. In consonance with this, higher CSF sCD14 lev-
els were associated with psychotic symptoms and paranoid 
and schizotypal personality traits, supporting a dimensional 
approach, independent of established diagnoses. Finally 
our study indicates moderate heritability estimates of the 
microglia CSF markers, high heritability estimates of T-tau, 
and the amyloid metabolism markers, whereas the markers 
of Alzheimer’s disease (AβX-42, Aβ1-42 and P-tau) were 
affected by dominant genetic influences. The study provides 
further evidence to the hypothesis of CNS inflammation in 
psychotic disorders and a possible significant role of sCD14.
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